Keros Therapeutics, Inc. (KROS) › Cash & EquivalentsKeros Therapeutics, Inc. (KROS) — Cash & EquivalentsAnnual figures by fiscal year, from SEC filings.2019: $7.02M2020: $265.88M2021: $230.04M2022: $279.05M2023: $331.15M2024: $559.93M2025: $287.42M$287.42M2019Cash & Equivalents (USD)2025Fiscal YearCash & EquivalentsChange YoY2025$287.42M-48.7%2024$559.93M+69.1%2023$331.15M+18.7%2022$279.05M+21.3%2021$230.04M-13.5%2020$265.88M+3687.4%2019$7.02M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per Share